Diurnal

  • Investment summary:

    Diurnal is a pharmaceutical company creating innovative, high-value hormone therapeutics and advanced treatment regimens of approved drugs.

    A Finance Wales syndicate co-investment with private sector and angel investors, Diurnal used initial and follow-on equity investment to secure patent on products and completed the first round of clinical trials towards commercialisation.

  • Total investment:
    undisclosed
  • Total Finance Wales investment:
    undisclosed
  • Investment type:
    Equity
  • Purpose:
    Tech ventures
  • Executives:
    Paul Lee